^
    Back
    Association details:
    Biomarker:FGFR3 S249C
    Cancer:Urothelial Cancer
    Drug:Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    BJU Int
    Title:

    Spectrum of genomic alterations in FGFR 3 : current appraisal of the potential role of FGFR 3 in advanced urothelial carcinoma

    Excerpt:
    To explain this patient's robust outlier response to pazopanib, we genomically analysed the tumour using targeted mutation profiling (Foundation Medicine, Cambridge, MA, USA), which revealed a sole activating mutation in FGFR3 (S249C). The sole presence of a mechanistically confirmed activating mutation and potent response to pazopanib is consistent with the hypothesis that FGFR3 was a molecular driver in this patient with UC...
    DOI:
    https://doi.org/10.1111/bju.13552